MedTrace Logo

A Study Assessing GW870086's Potential to Cause Skin Thinning

NCT01381445 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2017-07-21

No results posted yet for this study

Summary

This study is a randomised, double-blind, placebo-controlled study of topical GW870086 to explore the potential for skin thinning in healthy adult volunteers after 42±2 days of treatment. Twenty (20) healthy volunteers will be randomised to receive placebo and GW870086 2% cream, they will also receive either of the following treatments: GW870086 0.2% cream, or clobetasol propionate 0.05% cream.

Conditions

  • Dermatitis, Atopic

Interventions

DRUG

GW870086 0.2%

White to slightly coloured opaque cream

DRUG

GW870086 2%

White to slightly coloured opaque cream

DRUG

Clobetasol Propionate

White cream

DRUG

Placebo

White to slightly coloured opaque cream

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-04-14
Primary Completion
2011-07-07
Completion
2011-07-07

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01381445 on ClinicalTrials.gov